Status:
UNKNOWN
Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients
Lead Sponsor:
Assiut University
Conditions:
Galectin-3 and Pemphigus
Eligibility:
All Genders
Brief Summary
Assessment of the expression of galectin-3 in serum and saliva of pemphigus patients and compare it with age and sex matched controls. We want to detect whether a correlation exists between galectin-3...
Detailed Description
Pemphigus is a potentially life- threatening immune mediated bullous disease that affects the skin and mucous membranes with a significant impact on quality of life (1). It is due to production of aut...
Eligibility Criteria
Inclusion
- Patients with active stage of pemphigus.
Exclusion
- Patients who were on topical ttt, systemic corticosteroids or other immunosuppressive drugs in the last one month.
- Patients with disease attack duration more than 1 week.
- Patients with any other concomitant dermatological or chronic systemic diseases.
- \-
Key Trial Info
Start Date :
August 8 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2024
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05992727
Start Date
August 8 2023
End Date
March 1 2024
Last Update
August 15 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.